Scrutinizing Reverse-Payment Settlements

Law360, New York (December 16, 2011, 3:09 PM EST) -- Settlements of Hatch-Waxman litigation between branded and generic pharmaceutical companies that include a “reverse payment” by the branded firm to the generic have been the subject of significant antitrust litigation over the past several years.

Courts have not tended to use either a “per se” or “rule of reason” analysis, instead adopting a “scope of the patent” test to review such settlements.

This approach takes into account the particularized regulatory and patent enforcement framework under the Hatch-Waxman Act that governs both the relationship between branded and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.